Investors in Rigel Pharmaceuticals (RIGL)
got another very much unwanted dose of bad (or at least confusing) data
on Thursday, with disappointing OSKIRA-4 Phase 2 data on fostamatinib.
While there are additional studies still under way and scenarios under
which this drug could still make it, Rigel Pharmaceuticals is well on
its way to being one of my worst biotech calls, and the risk on this
stock is definitely running high.
Please read more here:
The Occultation Of Rigel Pharmaceuticals
No comments:
Post a Comment